Maynard Um
-
-
-
-
-
-
-
Guggenheim Downgrades Rapt Therapeutics (RAPT) to Neutral
-
-
-
-
-
-
-
Guggenheim Starts Rapt Therapeutics (RAPT) at Buy, PT $70
-
-
-
-
-
-
-
Leerink Partners Upgrades Rapt Therapeutics (RAPT) to Outperform
-
-
-
-
-
-
-
RAPT Therapeutics (RAPT) Sets June 16 as Effective Date of 1:8 Reverse Share Split
-
-
-
-
-
-
-
RAPT Therapeutics (RAPT) Announces $150M Private Placement
-
-
-
-
-
-
-
RAPT Therapeutics (RAPT): Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
-
-
396,470 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

